Response to the letter to the editor by Fernández-Fernández et al. entitled 'Effectiveness of alirocumab and evolocumab (PCSK9i) in the treatment of hypercholesterolemia' in relation to the article published by Bosch et al. (Medicina Clínica 2024;163:317-322).
作者信息
Bosch Montserrat, Ballarín Elena, Danés Immaculada
机构信息
Clinical Pharmacology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, España; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, España; Clinical Pharmacology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, España.
Clinical Pharmacology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, España; Clinical Pharmacology Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, España.
出版信息
Med Clin (Barc). 2025 Aug 30;165(5):107148. doi: 10.1016/j.medcli.2025.107148.
Zotero 插件